AIBOTICS, INC. completed an acquisition involving Philon Labs, LLC for Preferred Stock with a face value of $2,000,000 (closed 2023-11-28).
“Way” products. In consideration for the acquisition of the Assets, Mycotopia Therapies will issue a new class of Preferred Stock (the “Preferred Stock”) with a face value of $2,000,000, convertible into shares of the Company’s Common Stock (the “Common Stock”). All shares of Preferred Stock and Common Stock issued in conjunction with the transaction will be”
Auditor Changes
AIBOTICS, INC. reported that prior financial statements should not be relied upon.
“the Company’s management concluded that its previously issued (i) audited balance sheet and consolidated statement of operations for the period ending December 31, 2022, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 30, 2023; and (ii) unaudited interim financial statements for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022, filed on Form 10-Q, should be restated.”
Material Agreements
AIBOTICS, INC. terminated Agreement and Plan of Merger with PSLY.com (effective 2023-02-16).
“On May 18, 2022, Mycotopia Therapies Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Agreement”) whereby the Company was to merge with a wholly owned subsidiary of PSLY.com. Simultaneously E.iVentures, Inc. (“E.i”) was to merge with a separate wholly owned subsidiary of PSLY.com. On February 16, 2023, the parties to the Agreement mutually agreed to terminate the Agreement and release each other.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.